Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of VN-0200 in Japanese healthy adults and elderly subjects
jRCT2031210069Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing VN-0200 with Placebo (2 arms). Primary endpoint: Safety endpoints. Started Jun 2021; status: completed.
02
Drugs
VAGA-9001a + MABH-9002b
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031210069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210069.